NEW YORK (GenomeWeb News) — Shares in Vermillion, formerly Ciphergen Biosystems, were up 9.3 percent, or $.08, at $.94 in mid-afternoon trading today after the company published findings showing how a protein biomarker may help diagnose peripheral artery disease.
 
Specifically, the findings suggest that the biomarker, called beta-2 microglobulin, is elevated in patients with PAD and that the level of the protein is correlated with the severity of the disease.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Seattle Times writes that pharmacogenomics testing can help choose medications that may work best for people with depression.

Researchers report that deleting one gene from butterflies affects their wing coloration patterns, according to the Washington Post.

In PNAS this week: genome sequencing of weevil symbionts, retinoid X receptor deletion in lung cancer metastasis, and more.

Sequencing could help combat foodborne illnesses, according to a blog post by Food and Drug Administration officials.